Sealife Pharma GmbH is an innovative drug development company focused on delivering new
first in class antibiotics derived from the chemical diversity of marine fungi (also known as
microbes or bugs from the sea).
Sealife has fully equipped synthetic and analytical chemistry as well as microbial and cell biology laboratories and is based in Austria at the Technopark 1, Tulln.
Besides developing novel antibiotics to fight multi-drug resistant infections, Sealife also provides CRO
services to the pharmaceutical sector.
To support the companies activities in pharmaceutical development and engagement in the registration of a new active substance in Biocidal/MedTech market, SeaLifeвЂ™s shareholders to increase capital from shareholder funds in July 2015.
SeaLife secures fresh funding from a basic grant of The Austrian Research Promotion Agency (FFG) in May 2015. The fund supports the development of SeaLifeвЂ™s polymeric agent SLP0901 to enter the market as new active substance in the Biocide/MedTech field.
SeaLife Pharma GmbH is proud to announce that it has partnered in the EU FP7 funded project named Macumba - Marine Microorganisms: Cultivation Methods for Improving their Biotechnological Applications, with a total funding of 12 Mio в‚¬ and 23 partners from 11 nations.